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Stroke is the leading neurological cause of death 
and  severe  long-term  disability  in  developed 
countries  (Rosamond  et  al.,  2008),  although 
functional outcome after stroke is still largely 
unpredictable (Baird et al., 2001; Weimar et al., 
2002; Muir et al., 2006). Patients initially show-
ing a similar clinical picture can improve dra-
matically or worsen during the first days after 
stroke (Castillo, 1999; Baird, 2007). The presence 
of apoptotic neurons in the ischemic penumbra 
(Sairanen et al., 2006) and perihematoma area 
(Qureshi et al., 2003) may account for the im-
paired functional recovery of patients (Broughton 
et al., 2009) after ischemic stroke and intracere-
bral hemorrhage (ICH), respectively. Thus, the 
highly  variable  prediction  of  functional  out-
come after stroke could be the effect of differ-
ent genetic backgrounds to apoptosis.
Tp53 encodes the p53 transcription factor, 
a  tumor  suppressor  protein  that  mediates 
apoptosis in eukaryotic cells. Several polymor-
phisms have been identified within the Tp53 
gene, both in noncoding (introns) and coding 
(exons) regions (Olivier et al., 2002; Pietsch   
et al., 2006). The best studied human Tp53 
polymorphisms include the codon 72 (exon 4) 
single nucleotide polymorphism (SNP), which 
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The functional outcome after stroke is unpredictable; it is not accurately predicted by 
clinical pictures upon hospital admission. The presence of apoptotic neurons in the isch-
emic penumbra and perihematoma area may account for poor prognosis, but whether the 
highly variable stroke outcome reflects differences in genetic susceptibility to apoptosis is 
elusive. The p53 tumor suppressor protein, an important transcriptional regulator of 
apoptosis, naturally occurs in humans in two variants with single nucleotide polymor-
phisms resulting in Arg or Pro at residue 72. We show that poor functional outcome after 
either ischemic or hemorrhagic stroke was linked to the Arg/Arg genotype. This genotype 
was also associated with early neurological deterioration in ischemic stroke and with 
increased residual cavity volume in intracerebral hemorrhage. In primary cultured neurons, 
Arg72-p53, but not Pro72-p53, interacted directly with mitochondrial Bcl-xL and activated 
the intrinsic apoptotic pathway, increasing vulnerability to ischemia-induced apoptotic 
cell death. These results suggest that the Tp53 Arg/Arg genotype governs neuronal vulner-
ability to apoptosis and can be considered as a genetic marker predicting poor functional 
outcome after stroke.
© 2011 Gomez-Sanchez et al.  This article is distributed under the terms of an 
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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RESULTS AND DISCUSSION
The Tp53 Arg/Arg genotype is associated  
with poor functional outcome after stroke
Using the modified Rankin Scale (mRS; Sulter et al., 1999) 
to evaluate the disability or dependence in daily living activ-
ities of stroke victims (see Table S1 for baseline characteristics 
of patients), we found a median mRS score of 3 in patients 
harboring the Arg/Arg genotype at 3 mo after ischemic stroke. 
This mRS score was significantly higher than those found in 
Arg/Pro or Pro/Pro patients (Fig. 1 A and Fig. S1 A). However, 
no significant differences were found between groups of patients 
heterozygous and homozygous for the Pro allele (Fig. 1 A and 
Fig. S1 A), suggesting that this allele likely exerts a dominant 
effect over Arg (Biros et al., 2002; Bonafé et al., 2004). In ICH 
patients, we found that the mRS score was also significantly 
higher  in  Arg/Arg  patients  than  in  those  harboring  the   
Arg/Pro or Pro/Pro genotypes; carriers of the Pro allele showed 
a similar mRS score in ICH (Fig. 1 B and Fig. S1 B), as was 
also observed in ischemic stroke (Fig. 1 A and Fig. S1 A). 
Moreover, the percentage of patients with poor functional 
outcome (mRS > 2; Sulter et al., 1999) at 3 mo after either 
ischemic stroke or ICH was significantly higher in patients 
harboring the Arg/Arg genotype than in those with Arg/Pro 
or Pro/Pro genotypes in both cohorts studied (Table I).
leads  to  arginine-proline  substitution  (Arg72Pro),  and  a   
16-bp duplication in intron 3 (Ins16bp; Pietsch et al., 2006).   
In contrast to Ins16bp polymorphism, the Arg72Pro SNP 
occurs in a proline-rich domain involved in the proapop-
totic  function  of  p53  (Sakamuro  et  al.,  1997;  Pietsch   
et al., 2006). Thus, the Arg72 variant of p53 is a more potent 
inducer of apoptosis and inhibitor of oncogenic transforma-
tion than the Pro72 variant (Dumont et al., 2003; Bonafé   
et al., 2004; Zhu et al., 2010), and this determines cancer 
progression, the age of onset, and the survival of individuals 
harboring the Arg72Pro SNP (Pietsch et al., 2006; Whibley 
et al., 2009).
In this paper, we aimed to investigate, using two inde-
pendent  hospital-based  prospective  cohorts  of  patients, 
whether  the  Tp53  polymorphism  affecting  the  apoptotic 
function of p53 (Arg72Pro) explains the differential func-
tional outcome of individuals after stroke. To gain further 
support for the conclusions, we also included in the study 
haplotype  analysis  of  the  Ins16bp  polymorphism.  Finally,   
the molecular mechanism of apoptotic death caused by the 
Arg72Pro SNP variants was also investigated in cortical neu-
rons in primary culture.
Figure 1.  Tp53 codon 72 polymorphism (Arg72Pro) 
determines functional outcome after ischemic stroke 
or ICH. Patients were admitted at the University Hospital 
of Santiago de Compostela (Galicia, Spain). The study 
included 408 (Arg/Arg: 235; Arg/Pro: 147; Pro/Pro: 26) 
patients with ischemic stroke (A and C) and 128 (Arg/Arg: 
67; Arg/Pro: 54; Pro/Pro: 7) patients with ICH (B and D–F). 
Scores of the mRS (A and B), infarct volume (C), initial 
lesion volume (D), perihematoma edema volume (E), and 
residual cavity volume (F) were measured in patients with 
indicated Tp53 codon 72 genotypes. Ischemic stroke  
(G) and ICH (H) patients were also classified according to 
Ins16bp polymorphic variants (A1/A1, A1/A2, and A2/A2 
genotypes) and mRS scores were measured. Box plots 
show median values (horizontal line inside the box), quar-
tiles (box boundaries), and the largest and smallest ob-
served values (error bars). Points represent mean values 
and error bars indicate standard deviation. **, P < 0.001 
compared with Arg/Arg genotype.
Table I.  Functional outcome after stroke according to Tp53 Arg72Pro genotypes
Genotype Ischemic stroke ICH
Cohort 1 (P < 0.0001) Cohort 2 (P = 0.020) Cohort 1 (P < 0.0001) Cohort 2 (P = 0.004)
Good prognosis Poor prognosis Good prognosis Poor prognosis Good prognosis Poor prognosis Good prognosis Poor prognosis
Arg/Arg 104 (44.3) 131 (55.7) 35 (57.4) 26 (42.6) 13 (19.4) 54 (80.6) 8 (26.7) 22 (73.3)
Arg/Pro 117 (79.6) 30 (20.4) 27 (77.1) 8 (22.9) 49 (90.7) 5 (9.3) 12 (75.0) 4 (25.0)
Pro/Pro 26 (100) 0 7 (100) 0 7 (100) 0 2 (100) 0
Cohort 1: patients were admitted at the University Hospital of Santiago de Compostela (Galicia, Spain). Cohort 2: patients were admitted at the University Hospital of 
Germans Trias i Pujol (Catalonia, Spain). Functional outcome was evaluated at 3 mo using the mRS. An mRS score >2 was considered poor prognosis. Data are numbers (%). 
Data were compared among genotype groups using the 2 test.JEM VOL. 208, March 14, 2011  431
Brief Definitive Report
Table II.  Univariate analysis of variables according to prognosis in stroke patients
Variable Ischemic stroke ICH
  Good prognosis  
n = 247
Poor prognosis 
 n = 161
P value Good prognosis  
n = 69
Poor prognosis  
n = 59
P-value
Age, years 70.1 (11.7) 78.8 (9.9) <0.0001 69.3 (13.6) 76.4 (9.5) 0.009
Males, % 68.0 46.0 <0.0001 56.5 59.3 0.445
Hypertension, % 51.1 64.6 0.007 55.1 55.9 0.532
Diabetes, % 27.1 24.8 0.347 10.1 28.8 0.007
Smoking, % 17.4 8.1 0.005 10.1 11.9 0.487
Heavy alcohol intake, % 9.3 7.5 0.321 17.4 11.9 0.267
Hyperlipidemia, % 33.2 28.6 0.191
Coronary disease, % 13.8 14.3 0.496 5.8 10.2 0.278
Atrial fibrillation, % 14.6 24.8 0.007 15.9 10.2 0.244
SBP, mm Hg 148.5 (25.9) 155.6 (28.1) 0.049 154.5 (30.2) 165.9 (28.7) 0.097
DBP, mm Hg 81.7 (3.9) 82.5 (14.7) 0.708 88.6 (17.8) 87.6 (16.8) 0.745
Temperature, °C 36.3 (0.5) 36.3 (0.5) 0.296 36.3 (0.5) 36. (0.8) 0.867
Bood glucose, mg/dl 132.7 (60.5) 140.2 (60.6) <0.0001 114.5 (28.5) 134.8 (41.8) 0.007
Leukocytes, ×103/ml 8.2 (2.4) 9.0 (2.8) <0.0001 8.3 (2.3) 9.4 (3.3) 0.072
Platelet number, ×103/ml 231.1 (65.8) 255.3 (70.0) 0.045 219.8 (52.7) 246.6 (117.1) 0.525
INR 1.1 (0.3) 1.1 (0.2) 0.003 1.2 (0.5) 1.2 (0.5) 0.270
Fibrinogen, mg/dL 452.9 (103.8) 526.9 (130.7) <0.0001 453.8 (120.5) 504.6 (113.7) 0.161
hs-CRP, mg/dL 1.6 (2.4) 4.6 (7.9) <0.0001 3.7 (6.8) 5.7 (8.9) 0.083
NIHSS 3 [1, 5] 11 [6, 17] <0.0001 3 [2,6] 10 [8,15] <0.0001
END, % 1.6 24.8 <0.0001
Infarct Volume, ml 10.4 (16.0) 58.8 (81.1) <0.0001
TOAST: 0.006
-Cardioembolic, % 30.4 45.3
-Atherothrombotic, % 10.1 8.1
-Lacunar, % 15.0 5.6
-Undetermined, % 42.1 39.1
-Others, % 2.4 1.9
ICH volume on admission, ml 11.2 (11.4) 27.5 (37.8) <0.0001
Edema volume, ml 7.5 (12.9) 28.8 (36.0) <0.0001
Topography: 0.232
-Cerebellar % 4.3 6.8
-Deep % 65.2 50.8
-Lobar % 24.6 40.7
-Brain stem % 4.3 1.7
-Primary intraventricular, % 1.4 0
Ventricular extension, % 14.5 40.7 0.001
Etiology: 0.318
-Hypertensive, % 63.8 54.2
-Anticoagulant, % 13.0 15.3
-Amyloid, % 2.9 10.2
-Undetermined, % 19.8 17.0
Tp53 Arg72Pro polymorphism <0.0001 <0.0001
-Arg/Arg genotype, % 42.1 81.4 18.8 91.5
-Arg/Pro genotype, % 47.4 18.6 71.0 8.5
-Pro/Pro genotype, % 10.5 0 10.2 0
Patients were admitted at the University Hospital of Santiago de Compostela (Galicia, Spain; cohort 1). Functional outcome was evaluated at 3 mo using the mRS. An mRS 
score >2 was considered poor prognosis. Data are numbers (%), means (SD), or medians [quartiles]. Data were compared among prognosis groups (goor prognosis vs. poor 
prognosis) using the 2 test (proportions), the Student’s t test (continuous variables with normal distribution), or the Mann-Whitney test (continuous variables without  
normal distribution, NIHSS). SBP, systolic blood pressure; DBP, diastolic blood pressure; INR, international normalized ratio; hs-CRP, high sensitivity C-reactive protein. 
Univariate analysis of variables from cohort 2 (Catalonia, Spain) is shown in Table S2.432 Tp53 polymorphism influences stroke prognosis | Gomez-Sanchez et al.
infarct volume (B 5.51 [95% CI 16.70, 5.69], P = 0.384) 
after adjustment for age, atrial fibrillation, diagnosis (lacunar 
versus nonlacunar), leukocyte levels, fibrinogen, high sensitiv-
ity C-reactive protein, and NIHSS at admission. Accordingly, 
we  matched  all  patients  for  acute  infarct  volume  and  we 
found that the proportion of patients with poor functional 
outcome was always higher in Arg/Arg patients when com-
pared with Arg/Pro or Pro/Pro, independently on the infarct 
volume (Table S4).
In the ICH patients, no differences were found in the   
lesion volume (Fig. 1 D) and perihematoma edema volume 
(Fig. 1 E) among genotypes, but a five- to sevenfold higher 
residual cavity volume was found in Arg/Arg when compared 
with Arg/Pro or Pro/Pro genotypes (Fig. 1 F). Further multi-
ple linear regression analysis confirmed that Arg/Arg geno-
type was an independent marker for residual cavity volume   
(B 15.40 [95% CI 12.17, 18.62], P < 0.0001) after adjustment 
for  a  history  of  diabetes,  leukocyte  counts,  platelet  count,   
hematoma volume, perihematoma edema volume, ventricular 
extension, and NIHSS upon admission. These data further 
support the link between Arg/Arg genotype with poor prog-
nosis after stroke, with good prognosis being mainly restricted 
to stroke patients with the Arg/Pro or the Pro/Pro genotypes.
We next aimed to elucidate whether other naturally oc-
curring Tp53 genotype would also explain functional prog-
nosis after stroke. We focused on the Ins16bp polymorphism 
(Pietsch et al., 2006), an insertion on Tp53 intron 3 genotype 
that, being nearby codon 72 polymorphism in exon 4, might 
potentially explain the proposed association of this allele with 
poor prognosis in stroke. However, we found no association 
between Ins16bp genotype and functional prognosis after   
either ischemic stroke (Fig. 1 G) or ICH (Fig. 1 H), despite 
showing very similar allelic frequencies to those in the Arg-
72Pro genotypes (Table S1). Such similarities in the allelic 
frequencies of both polymorphisms confirm earlier studies 
performed  in  healthy  subjects  from  European  populations 
(Santos et al., 2006; Costa et al., 2008). Thus, functional prognosis 
Next, we analyzed baseline demographic and clinical fea-
tures of stroke patients by outcome groups. We found that the 
vast majority of Arg/Arg patients (81.4 and 76.5%) had poor 
functional  outcome  after  ischemic  stroke,  whereas  only  a 
small proportion of Arg/Pro (18.6 and 23.5%) and none of the 
Pro/Pro patients showed poor prognosis in the two indepen-
dent cohorts studied (Table II and Table S2). Furthermore, 
the Arg/Arg genotype was an independent marker of poor 
functional outcome, as revealed by logistic regression analysis 
after adjustment for age, National Institutes of Health Stroke 
Scale (NIHSS) score on admission, infarct volume, and early 
neurological  deterioration  (END; Table  III  and Table  S3). 
Regarding the ICH group, most Arg/Arg patients (91.5 and 
84.6%) had poor functional outcome, whereas this was mini-
mum (8.5 and 15.4%) in Arg/Pro and zero in Pro/Pro patients 
(Table II and Table S2). Moreover, the Arg/Arg genotype was 
found to be a highly independent marker of poor prognosis 
after adjustment for age, diabetes, blood glucose, ICH volume, 
perihematoma  edema,  ventricular  extension,  and  NIHSS 
upon admission (Table III and Table S3). These results reveal, 
for the first time, that the Tp53 Arg72Pro SNP strongly deter-
mines functional outcome after stroke, regardless of whether 
the origin is ischemic or hemorrhagic.
We next analyzed whether the Arg72Pro SNP was associ-
ated with secondary variables. END, a common complication 
associated with poor prognosis after ischemic stroke (Castillo 
et al., 1997; Kwan and Hand, 2006), was more frequent in 
Arg/Arg (17.4%) than in Arg/Pro (2%) or Pro/Pro (0%) geno-
types  (P  <  0.0001).  Moreover,  the  Arg/Arg  genotype  was 
found to be an independent marker of END (odds ratio [OR] 
7.77 [95% confidence interval (CI) 1.72, 35.01], P = 0.008) 
after adjustment for age, diastolic blood pressure, temperature, 
glucose levels, fibrinogen, high sensitivity C-reactive protein, 
and NHISS upon admission. The infarct volume values were 
also  significantly  higher  in  Arg/Arg  when  compared  with 
Arg/Pro or Pro/Pro genotypes (Fig. 1 C); however, we found 
no independent association between Arg/Arg genotype and 
Table III.  Logistic regression analysis showing independent variables associated with poor functional outcome at 3 mo (mRS > 
2) after stroke
Variable Ischemic stroke ICH
OR 95% CI P-value OR 95% CI P-value
Age 1.05 1.00–1.09 0.013 1.07 0.99–1.15 0.059
Diabetes 0.70 0.10–4.86 0.720
Blood glucose 0.99 0.97–1.01 0.720
ICH volume 0.99 0.95–1.03 0.745
Edema volume 1.02 0.97–1.08 0.334
Ventricular Extension 4.82 0.69–33.5 0.112
NIHSS on admission 1.33 1.20–1.48 <0.0001 1.42 1.16–1.72 <0.0001
Infarct volume 1.01 1.00–1.03 0.035
END 15.29 2.58–90.62 0.003
Arg/Arg genotype 3.89 1.63–9.28 0.002 360.7 31.5–4,132.1 <0.0001
Patients were admitted at the University Hospital of Santiago de Compostela (Galicia, Spain; cohort 1). OR and their 95% CI were calculated to demonstrate the independent 
association between poor prognosis and Arg/Arg genotype. Analysis of variables from cohort 2 (Catalonia, Spain) is shown in Table S3.JEM VOL. 208, March 14, 2011  433
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after stroke is strongly associated with Arg72Pro SNP and is 
independent from the potentially nearby linkage disequilib-
rium associated with the Ins16bp polymorphism.
The Arg72-p53 polymorphic variant triggers neuronal death 
via the mitochondrial apoptotic pathway
Recent studies have shown the occurrence of delayed (days to 
weeks) apoptotic neuronal death in the surrounding area of 
the necrotic core, leading to the propagation of brain damage 
(Broughton  et  al.,  2009).  Because  the  ischemic  penumbra 
(Sairanen et al., 2006) and perihematoma area (Qureshi et al., 
2003) show apoptotic neurons that might explain functional 
outcomes after stroke (Broughton et al., 2009), we next aimed 
to elucidate whether different Arg72Pro genotypes can deter-
mine neuronal apoptotic phenotypes. Rat cortical primary 
neurons (Fig. 2 B and Fig. S1 C) and human neuron-like cells 
(Fig. S1 D) expressing human Arg72-p53 displayed a clearer 
apoptotic phenotype than those expressing Pro72-p53, despite 
the  fact  that  both  proteins  identically  transactivated  p53 
downstream targets p21 and proapoptotic Bax, PUMA, PERP, 
and AIP1 (Fig. 2 A). Interestingly, pifithrin  (PFT-), an   
inhibitor of p53-mediated transcriptional activa-
tion (Zhu et al., 2002; Fig. S1 E), fully prevented 
the modest Pro72-p53–induced apoptosis with-
out  affecting  that  of Arg72-p53  (Fig.  2  C).  It 
should therefore be noted that in rodents the 
codon 72 Tp53 gene exclusively encodes Pro72-p53 
(Pietsch et al., 2006), hence explaining why in 
previous studies PFT- can improve the recovery 
of ischemic brain in the rat (Luo et al., 2009). 
Thus, neuronal apoptotic death by the human-
specific Arg72-p53  occurs  through  a  transcrip-
tional-independent  mechanism  not  resembling 
rodent cell death by p53.
To understand how Arg72-p53 triggered neuronal apop-
totic death, we first used a battery of caspase activity inhibi-
tors. We found that, besides the general caspase inhibitors 
ZVAD and ZDEVD, the highly specific caspase 3 activity 
inhibitor ZDQMD prevented Arg72-p53–induced neuronal 
apoptosis (Fig. 2 D). Caspase 3 can be activated by either the 
mitochondrial-independent caspases 8 and 2 or the mito-
chondrial-dependent caspase 9; however, inhibition of cas-
pases 8 (ZIETD) or 2 (ZVDVAD) were ineffective, whereas 
inhibition of caspase 9 with ZLEHD fully prevented Arg72-
p53–mediated neuronal apoptosis (Fig. 2 D). Moreover, active 
caspase 3 and cleaved PARP-1 staining were detected in 30 
and 27%, respectively, of enhanced (E) GFP+ neurons effi-
ciently expressing Arg72-p53 but very modestly in those neu-
rons  expressing  Pro72-p53  (Fig.  2  E).  Neurons  expressing 
Pro72-p53 showed intact mitochondrial membrane potential 
(m), in contrast to those expressing Arg72-p53 which col-
lapsed their m (Fig. 2 F and Fig. S1 F). Together, these re-
sults suggest that Arg72-p53 triggers neuronal apoptotic death 
through the mitochondrial (intrinsic) apoptotic pathway.   
In good agreement with this notion, we further show that 
Figure 2.  Arg72-p53 triggers neuronal apoptotic 
death through the intrinsic pathway. (A) HEK293T cells 
were transfected with empty vector (control) or vector 
encoding Arg72-p53 or Pro72-p53. At indicated time points, 
proteins were measured by Western blotting. Black lines 
indicate that intervening lanes have been spliced out.  
(B) Rat cortical primary neurons were transfected with 
vectors encoding Arg72-p53-IRES-EGFP or Pro72-p53-IRES-
EGFP. Apoptosis of EGFP+ neurons was measured 14 or 24 h  
later. (C and D) Neurons transfected as in B were treated 
with the inhibitor of p53-mediated gene transactivation, 
PFT- (C), or with 100 µM of the general caspase inhibitors 
ZVAD or ZDEVD, 100 µM of the caspase 3 inhibitor ZDQMD, 
50 µM of the caspase 9 inhibitor ZLEHD, 100 µM of the 
caspase 8 inhibitor ZIETD, or 100 µM of the caspase 2 in-
hibitor ZVDVAD. Apoptosis was measured 14 h later.  
(E) Neurons transfected as in B were analyzed by flow  
cytometry. Histograms are gated on EGFP+ cells. (F) m 
was measured in neurons transfected as in B. The data in  
A and E represent four independent experiments. The data 
in B–D and F are means ± SEM of four different cell  
cultures. *, P < 0.05 compared with Pro72-p53.434 Tp53 polymorphism influences stroke prognosis | Gomez-Sanchez et al.
In summary, in this paper we show that the Tp53 Arg/Arg 
genotype is a genetic marker of poor functional prognosis   
after stroke. Interestingly, the Arg/Arg genotype is associated 
with good prognosis in anticancer treatments, and Arg72-p53 
protects cells against neoplastic development (Pietsch et al., 
2006; Whibley  et  al.,  2009). Thus,  proapoptotic Arg72-p53 
(Dumont et al., 2003; Bonafé et al., 2004; Zhu et al., 2010; this 
paper) in Arg/Arg subjects dictates both poor and good prog-
noses in stroke and cancer, respectively. This is in good agree-
ment with the recently highlighted notion that oncogenesis 
and neuronal death may share common mechanistic founda-
tions (Morris et al., 2010). Furthermore, it would be interest-
ing to know whether the prognostic value of the Arg/Arg 
genotype herein described for stroke outcome are also associ-
ated with Alzheimer’s or Parkinson’s Diseases, two neurode-
generative disorders in which apoptotic neuronal death is an 
underlying mechanism (Ribe et al., 2008; Levy et al., 2009).   
If so, our results may have wider pathophysiological implica-
tions that now need to be investigated.
MATERIALS AND METHODS
Patient cohorts. An observational prospective study was performed on two 
independent hospital-based cohorts of patients with ischemic stroke or non-
traumatic ICH. Inclusion criteria were patients admitted within the first   
12 h after the onset of symptoms, or from the start of sleep in those with 
symptoms upon awakening, who were previously independent for daily living 
activities (Table S1). Patients admitted to the University Hospital of Santiago 
de Compostela (Galicia, Spain) during the years 2006–2008 were enrolled in 
Arg72-p53, but not Pro72-p53, is localized in the mitochon-
dria and promotes cytochrome c release from the mitochon-
dria  to  the  cytosol  (Fig.  3 A).  Furthermore, Arg72-p53 
interacted directly with Bcl-xL in a much more potent fash-
ion than Pro72-p53 (Fig. 2 B and Fig. S1 G), and Bcl-xL over-
expression rescued the neuronal apoptotic death phenotype 
of Arg72-p53 (Fig. 3 C). Thus, it is conceivable that Arg72-p53 
translocates to mitochondria, where it directly binds to (and 
inactivates) Bcl-xL, thus inducing cytochrome c release to 
promote caspase 9 activation (Taylor et al., 2008).
We finally show that the Arg72-p53, but not the Pro72-p53 
variant, when expressed at subtoxic concentrations (Fig. 1 A), 
increased the vulnerability of neurons to glutamate receptor 
activation and oxygen/glucose deprivation (Fig. 3, D and E)—
two  cellular  models  of  ischemic  damage  (Almeida  and   
Bolaños, 2001; Almeida et al., 2002; Maestre et al., 2008)—
through the intrinsic pathway (Fig. S1 H). This was further 
confirmed by expressing bacterial artificial chromosomes 
(BACs) containing the endogenous promoter-driven human 
p53 gene harboring either the Arg72 or the Pro72 allele in 
p53-null mice primary neurons. The results show that neu-
rons harboring the Arg72 allele (p53/Arg72) were more vul-
nerable  against  OGD-triggered  apoptotic  death  and  m 
disruption than those harboring the Pro72 one (p53/Pro72; 
Fig. 3 F), despite the fact that both polymorphic variants are 
equally sensitive to OGD-mediated p53 protein accumula-
tion (Fig. S1 I).
Figure 3.  Arg72-p53 interacts directly 
with mitochondrial Bcl-xL and increases 
neuronal vulnerability to ischemia- 
induced apoptosis. (A) HEK293T cells were 
transfected with Arg72-p53 or Pro72-p53.  
Cytoplasmic (cyto) and mitochondrial (mito) 
fractions were isolated and analyzed by West-
ern blotting. VDAC, control for the integrity of 
the mitochondria. PCNA, control indicating 
absence of nuclear contamination in the mi-
tochondrial fractions. Black lines indicate that 
intervening lanes have been spliced out.  
(B) Rat cortical primary neurons were trans-
fected with Arg72-p53-IRES-EGFP or Pro72-
p53-IRES-EGFP. p53 colocalization with Bcl-xL 
was analyzed by immunofluorescence.  
DAPI, nuclear staining. (C) Rat cortical  
primary neurons were transfected with  
Arg72-p53-IRES-EGFP, Pro72-p53-IRES-EGFP, 
or Arg72-p53-IRES-EGFP + Bcl-xL. Apoptosis 
was measured 14 h later. (D) Neurons were 
transfected with empty vector (control) or the 
minimum amount of Arg72-p53-IRES-EGFP or 
Arg72-p53-IRES-EGFP cDNA not altering neu-
ronal survival (0.08 µg/106 neurons) and were 
exposed to 100 µM glutamate for 5 min and 
incubated in culture medium for a further 8 h. Apoptosis was measured. (E) Neurons were transfected as described in D and were exposed to oxygen and 
glucose deprivation (OGD) for 1 h. Apoptosis was measured. (F) Neurons from Tp53/ mice were transfected with human BAC containing the entire Tp53 
gene locus encoding either proline (p53/Pro72) or arginine (p53/Arg72) and were exposed to oxygen and glucose deprivation (OGD) for 3 h. Apoptosis 
was measured. The data in A and B represent four independent experiments. The data in C–F are means ± SEM of four different cell cultures. *, P < 0.05 
compared with Pro72-p53; #, P < 0.05 compared with none in D or normoxia in E and F. Bar, 20 µM.JEM VOL. 208, March 14, 2011  435
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was detected by amplifying genomic DNA with the forward primer 5-TG-
CCGTTCCCCCTGACATCT-3  and  the  reverse  primer  5-CTGACC-
GTGCAAGTCACAGA-3. The 16-bp duplication polymorphism at intron 3 
(Ins16bp; rs17878362) was detected by amplifying genomic DNA with the 
forward  primer  5-CAGGGAAAAGGGGCACAGAC-3  and  the  reverse 
primer 5-CCTCCTCCCCACAACAAAACACC-3. Tp53 exon 4, where 
BstU1 RFLP is located, was amplified within a 298-bp DNA fragment. The 
Tp53 Ins16bp polymorphism was amplified within a 90-bp (no duplication, 
designated as the A1 allele) or a 106-bp (with 16-bp duplication, designated 
as the A2 allele) DNA fragment. Digests were separated on agarose gel (3.5%) 
and the ethidium bromide–stained fragments were analyzed under a UV 
source, using the Kodak Digital Science ID image analysis system. The distri-
bution of genotype frequencies in Arg72Pro and Ins16bp polymorphisms 
(Table S1) between the ischemic stroke and the ICH cohorts was within the 
Hardy-Weinberg equilibrium (P > 0.1 in all cases).
Cell  cultures,  transfections,  and  treatments. Animals were obtained 
from the Animal Experimentation Unit of the University of Salamanca, in 
accordance with Spanish legislation (RD 1201/2005) under license from the 
Spanish Ministry of Education and Science. Animal experiments were ap-
proved by the Bioethics Committee of the University of Salamanca and the 
Experimental Research Unit of the University Hospital of Salamanca. 
The mechanistic experiments were performed at the University Hospital of 
Salamanca. Primary cultures of cortical neurons were prepared from fetal 
(E16) Wistar rats. Cortical neurons were also obtained from fetal (E15) p53-null 
mice (Tp53/, The Jackson Laboratory; B6.129S2, donated by I. Garcia-
Higuera, Instituto de Biologia Molecular y Celular del Cancer, CSIC-Univer-
sity of Salamanca, Spain). Cells were seeded (2.0 × 105 cells/cm2) in DME 
(Sigma-Aldrich) supplemented with 10% (vol/vol) FCS (Roche) and incu-
bated at 37°C in a humidified 5% CO2-containing atmosphere. 48 h after 
plating, the medium was replaced with DME supplemented with 5% horse 
serum (Sigma-Aldrich) and with 20 mM d-glucose. On day 4, cytosine ara-
binoside (10 µM; Sigma-Aldrich) was added to prevent nonneuronal prolif-
eration (Almeida and Bolaños, 2001). Transfections in primary neurons were 
performed after 5 d in culture (Almeida et al., 2005). Human neuroblastoma 
SH-SY5Y cells were grown in DME supplemented with 10% (vol/vol) FCS. 
To induce neuronal differentiation of SH-SY5Y cells, they were seeded at 
104 cells/cm2 and all-trans RA (10 µM; Sigma-Aldrich) was added 24 h later. 
After 5 d, cells were washed three times with DME and further incubated 
with 50 ng/ml BDNF (PeproTech) for 24 h. Transfections of SH-SY5Y cells 
were performed after RA for 5 d, i.e., when cells displayed a terminally dif-
ferentiated neuronal-like phenotype (Almeida et al., 2005). Human embry-
onic kidney 293T (HEK293T) cells and human p53-null H1299 cells were 
maintained in DME supplemented with 10% (vol/vol) FCS.
Cells were transfected with the pIRES2-EGFP mammalian expression 
vector (Invitrogen) coexpressing the EGFP and either the full-length Arg72-p53 
or Pro72-p53 human cDNA using Lipofectamine 2000 (Invitrogen; Almeida 
et al., 2005). Neurons from Tp53/ mice and H1299 cells were transfected 
with human BACs containing the entire Tp53 gene locus encoding either 
arginine (Arg72) or proline (Pro72) at codon 72 (donated by D.G. Johnson, the 
University of Texas M.D. Anderson Cancer Center, Houston, TX; Zhu et al., 
2010) using Lipofectamine 2000. When indicated, cells were treated with 
100 µM glutamate for 5 min (Almeida and Bolaños, 2001; Maestre et al., 
2008) or exposed to oxygen and glucose deprivation (Almeida et al., 2002).
Flow cytometric analysis of apoptotic cell death. Neurons were stained 
with APC-conjugated  annexin-V  and  7-amino-actinomycin  D  (7-AAD; 
BD) and were analyzed on a FACSCalibur flow cytometer (BD). EGFP+ 
(transfected) annexin V–APC-stained cells that were 7-AAD-–negative were 
considered apoptotic (Almeida et al., 2005; Maestre et al., 2008).
Detection of caspase 3 activation. Active caspase 3 was detected in the 
transfected (EGFP+) neurons by flow cytometry, using the APO ACTIVE   
3 kit (Bachem). Flow cytometric detection of cleaved PARP-1 was performed 
using the 3-PE anticleaved PARP-1 monoclonal antibody (F21-852; BD).
the study (cohort 1). Of these, ischemic stroke patients receiving tissue plas-
minogen activator (tPA) treatment (59 intravenously; 6 intraarterially), those 
included in clinical trials (33), and those showing severe systemic disease (28) 
were excluded. Intracerebral hemorrhagic patients with structural brain ab-
normalities (3 arteriovenous malformations; 13 tumors) and those with 
severe systemic disease (9) were also excluded. In addition, some patients (24) 
refused to participate in the study, and 36 were lost during the followup. Two 
biological samples were not genotyped as a result of poor quantity of DNA. 
Thus, cohort 1 included 408 patients with ischemic stroke (male, 59.3%; 
mean age, 72.8 ± 12.1 yr) and 128 with ICH (male, 57.8%; mean age, 71.2 ± 
12.3 yr).
The second cohort of patients (cohort 2) was admitted to the University 
Hospital Germans Trias i Pujol (Catalonia, Spain) during the years 2006–
2008. Ischemic stroke patients receiving tPA treatment (182 intravenously; 22 
intraarterially), those included in clinical trials (57), and those showing severe 
systemic disease (12) were excluded. Intracerebral hemorrhagic patients with 
structural brain abnormalities (2 arteriovenous malformations; 11 tumors) 
and those included in clinical trials (17) were also excluded. Seven biological 
samples were not genotyped as a result of poor quantity of DNA. Finally, co-
hort 2 included 103 patients with ischemic stroke (male, 68.9%; mean age, 
67.4 ± 10.1 yr) and 48 with ICH (male, 76.6%; mean age, 67.1 ± 12.7 yr).
In all cases, the protocols were approved by the local Ethics Committee 
(Santiago de Compostela, Barcelona, and Salamanca) and by the institutional 
review boards of the University of Santiago de Compostela and the Univer-
sity of Salamanca. All patients or their relatives provided their informed con-
sent before taking part of the studies.
Clinical variables. Patients were admitted to the Acute Stroke Units and 
treated according to the Guidelines of the Cerebrovascular Disease Study 
Group of the Spanish Society of Neurology (2004). Medical history, potential 
vascular risk factors, blood and coagulation tests, 12-lead ECG, chest x-ray, 
and carotid ultrasonography, were recorded upon admission. Stroke subtypes 
were classified according to the TOAST criteria (Adams et al., 1993). Stroke 
severity was assessed by a certified neurologist using the NIHSS upon admis-
sion, and after 24 and 48 h. END was diagnosed in patients who worsened ≥4 
points (NIHSS score) within the first 48 h (Castillo et al., 1997; Kwan and 
Hand, 2006). Functional outcome was evaluated at 3 mo using the mRS 
(Table S5). mRS score >2 was considered poor outcome (Sulter et al., 1999; 
Banks and Marotta, 2007).
Neuroimaging studies. Ischemic stroke patients were subjected to com-
puted tomography (CT) scans upon admission and at days 4–7. The infarct 
volume was calculated in the second CT scan using the formula 0.5 × a × b × c, 
where a and b represent the largest perpendicular diameters, and c represents 
the slice thickness. Lesion volumes of the intracerebral hemorrhagic patients 
were determined by CT scans using the same formula. The hematoma vol-
ume was determined upon admission, and the perihematoma edema volume 
(total volume minus hematoma volume) in a second CT performed after 
48–72 h. The residual cavity volume was determined with CT at 3 mo ± 15 d. 
ICH topography was classified as lobar when it mainly affected the cortical 
or subcortical white matter of the cerebral lobes or as deep when it was lim-
ited to the internal capsule, the basal ganglia, or thalamus. The presence of 
ventricular extension of the hematoma was also recorded. All neuroimaging 
evaluations were performed by neuroradiologists blinded to the patients’ 
clinical and laboratory results.
Outcome variables. The main outcome measure for all patients was func-
tional status at 3 mo ± 15 d. In the case of the ischemic stroke patients, sec-
ondary variables were infarct volume and END. For ICH, the residual cavity 
volume was considered to be the secondary variable.
Tp53 polymorphism analysis. Genotyping of Tp53 polymorphisms was 
performed at the University of Salamanca, by authors blinded to the clinical 
status of patients, using the PCR-RFLP technique (Matlashewski et al., 1987; 
Lazar et al., 1993). The Tp53 SNP of exon 4 at codon 72 (Arg72Pro; rs1042522) 436 Tp53 polymorphism influences stroke prognosis | Gomez-Sanchez et al.
95% CIs. The results obtained in cell cultures are expressed as means ± SEM 
values from four different culture preparations. In these, statistical analyses were 
performed by one-way analysis of variance, followed by the least significant 
difference multiple range test. In these cases, P < 0.05 was considered signifi-
cant. The statistical analyses were conducted using SPSS 16.0 for Macintosh.
Online supplemental material. Fig. S1 shows that Arg72-p53 dictates 
poor prognosis after both ischemic stroke and intracerebral hemorrhage in 
the validation cohort and promotes apoptosis through the intrinsic path-
way in different cell types. Table S1 shows baseline characteristics of patients. 
Table S2 includes the univariate analysis of variables according to prognosis 
in stroke patients from cohort 2 (University Hospital of Germans Trias i 
Pujol, Catalonia, Spain). Logistic regression analysis showing independent 
variables associated with poor functional outcome at 3 mo after stroke in 
cohort 2 is shown in Table S3. Table S4 shows Tp53 Arg72Pro genotypes   
in stroke patients with poor prognosis matched for infarct volume. Table S5 
shows mRS. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20101523/DC1.
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